Centene (CNC) Investor Day 2024 summary
Event summary combining transcript, slides, and related documents.
Investor Day 2024 summary
8 Jul, 2026Strategic direction and growth opportunities
2025 adjusted EPS guidance is set above $7.25, representing over 6% year-over-year growth, with a long-term EPS CAGR target of 12%-15%.
Focus is on three core businesses—Medicaid, Medicare, and Marketplace—while highlighting disruptive growth in Duals alignment and ICHRA.
Medicaid remains the core, with presence in 30 states and 2,098 counties, and ongoing growth in managed care and complex populations.
Marketplace leadership is reinforced by 4.5 million members and over $30 billion in projected 2025 revenue, with a sustainable pre-tax margin target of 5%-7.5%.
ICHRA market entry is underway, with new plans launched in six states and partnerships to access over 500,000 employer groups.
Financial guidance and embedded earnings
2025 premium and service revenue guidance is $154.0–$156.0 billion, up from $143.5–$144.5 billion in 2024.
Medicaid expected to represent 55% of 2025 revenue, with a 3%-4% average net rate increase and ongoing rate recapture efforts.
Medicare segment targets break-even by 2027, with margin improvement driven by SG&A reductions and operational efficiencies.
PDP business projected at $14.5 billion in 2025 revenue, with a path to increase pre-tax margins from 1% to at least 3%.
Embedded earnings power identified in Medicaid margin normalization, Medicare turnaround, and PDP margin expansion, with scenario planning for potential eAPTC subsidy changes.
Policy and market environment
Political landscape remains divided but bipartisan support for Medicaid and Marketplace stability is strong, with enhanced APTCs likely to see some form of extension.
Ten states have not expanded Medicaid, representing a $2.65B opportunity if expansion occurs.
Medicare Advantage outlook includes more favorable rates and Star ratings, with a focus on duals integration and drug pricing innovation.
Marketplace growth is supported by eAPTCs, with contingency plans for subsidy expiration, including dual rate filings and pricing adjustments.
M&A remains a strategic option, with a focus on core business expansion and capabilities that accelerate disruptive opportunities.
Latest events from Centene
- Q2 2026 EPS hit $2.51 on $53.6B revenue, margins improved, and guidance was raised.CNC
Q2 202628 Jul 2026 - Q2 2025 saw higher revenues but a net loss from medical costs and Marketplace risk adjustment shortfall.CNC
Q2 20259 Jul 2026 - 2024 EPS rose 7% to $7.17; 2025 revenue guidance increased by $4B to $158–$160B.CNC
Q4 20248 Jul 2026 - 2026 guidance targets adjusted EPS above $3.00, with margin recovery and debt reduction focus.CNC
Q4 20258 Jul 2026 - Q1 2025 adjusted EPS up 28% to $2.90, revenue up 17% to $46.6B, guidance raised.CNC
Q1 20251 Jul 2026 - Q1 2026 EPS and revenues exceeded expectations, with improved leverage and strong segment results.CNC
Q1 202628 Apr 2026 - Operational disruption in 2025 drives strategic refocus, governance refresh, and margin recovery plans.CNC
Proxy filing26 Mar 2026 - Key votes include director elections, executive pay, auditor ratification, and board chair proposal.CNC
Proxy filing26 Mar 2026 - 2026 EPS guidance reaffirmed; core businesses on track, with focus on fraud prevention and risk adjustment.CNC
Barclays 28th Annual Global Healthcare Conference10 Mar 2026